NeuroQure, a leader in neurodevelopmental diagnostics, today announced the launch of its groundbreaking autism spectrum disorder (ASD) screening test. This innovative solution aims to revolutionize early detection and intervention for ASD.
Key Features
- Early detection capabilities
- Non-invasive testing process
- Comprehensive results analysis
- Integration with existing healthcare systems
The new screening test utilizes advanced calcium signaling biomarkers to provide accurate and reliable results. By analyzing subtle cellular indicators, the test significantly enhances early diagnosis, allowing for timely intervention.
Availability
NeuroQure's new screening test is now available nationwide through authorized healthcare providers.
Read the full paper on PubMed